| Dr Brian Patrick O'donnell, MD | |
|
407 Us Route 1, Freeport, ME 04032-7023 | |
| (207) 865-2023 | |
| (207) 865-2027 |
| Full Name | Dr Brian Patrick O'donnell |
|---|---|
| Gender | Male |
| Speciality | Dermatology - Mohs-micrographic Surgery |
| Location | 407 Us Route 1, Freeport, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285656413 | NPI | - | NPPES |
| 010527189 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ND0101X | Dermatology - Mohs-micrographic Surgery | MD13824 (Maine) | Primary |
| Entity Name | Mainegeneral Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669423380 PECOS PAC ID: 1254245715 Enrollment ID: O20031118000718 |
News Archive
The Pulmonary Fibrosis Foundation today announced that, in partnership with the American Thoracic Society (ATS) and Coalition for Pulmonary Fibrosis (CPF), $400,000 in new pulmonary fibrosis research grants as part of the 2010 ATS Partner Award Program for Pulmonary Fibrosis Research.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).
Reaction Progress Kinetic Analysis (RPKA) streamlines kinetic studies by exploiting extensive data available from accurate in situ monitoring of global reaction progress under synthetically relevant conditions, where the concentrations of two or more reactants are changing simultaneously – in fact, in the same manner that they are expected to change during practical synthesis.
Researchers from Children's Hospital of Philadelphia have shown there may be key genetic differences in the causes of attention-deficit hyperactivity disorder between African Americans and people of European ancestry, which may play an important part in how patients of different ethnic backgrounds respond to treatments for this condition.
Is it possible to share a pain that you observe in another but have never actually experienced yourself?
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian Patrick O'donnell, MD 407 Us Route 1, Freeport, ME 04032-7023 Ph: (207) 865-2023 | Dr Brian Patrick O'donnell, MD 407 Us Route 1, Freeport, ME 04032-7023 Ph: (207) 865-2023 |
News Archive
The Pulmonary Fibrosis Foundation today announced that, in partnership with the American Thoracic Society (ATS) and Coalition for Pulmonary Fibrosis (CPF), $400,000 in new pulmonary fibrosis research grants as part of the 2010 ATS Partner Award Program for Pulmonary Fibrosis Research.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated a Phase 2 clinical trial evaluating SCH 900105 (also referred to as AV-299) for the treatment of non-small cell lung cancer. The initiation of this trial triggers an $8.5 million milestone payment by Merck to AVEO resulting from a 2007 agreement between AVEO and Schering-Plough (now Merck).
Reaction Progress Kinetic Analysis (RPKA) streamlines kinetic studies by exploiting extensive data available from accurate in situ monitoring of global reaction progress under synthetically relevant conditions, where the concentrations of two or more reactants are changing simultaneously – in fact, in the same manner that they are expected to change during practical synthesis.
Researchers from Children's Hospital of Philadelphia have shown there may be key genetic differences in the causes of attention-deficit hyperactivity disorder between African Americans and people of European ancestry, which may play an important part in how patients of different ethnic backgrounds respond to treatments for this condition.
Is it possible to share a pain that you observe in another but have never actually experienced yourself?
› Verified 1 days ago